Management of locally advanced and metastatic colon cancer in elderly patients

Abstract

Colon cancer is the second leading cause of cancer mortality in the United States with a median age at diagnosis of 69 years. Sixty percent are diagnosed over the age of 65 years and 36% are 75 years or older. At diagnosis, approximately 58% of patients will have locally advanced and metastatic disease, for which systemic chemotherapy has been shown to improve survival. Treatment of cancer in elderly patients is more challenging due to multiple factors, including disabling co-morbidities as well as a decline in organ function. Cancer treatment of elderly patients is often associated with more toxicities that may lead to frequent hospitalizations. In locally advanced disease, fewer older patients receive adjuvant chemotherapy despite survival benefit and similar toxicity when compared to their younger counterparts. A survival benefit is also observed in the palliative chemotherapy setting for elderly patients with metastatic disease. When treating elderly patients with colon cancer, one has to consider drug pharmacokinetics and pharmacodynamics. Since chronological age is a poor marker of a patient's functional status, several methods of functional assessment including performance status and activities of daily living (ADL) or instrumental ADL, or even a comprehensive geriatric assessment, may be used. There is no ideal chemotherapy regimen that fits all elderly patients and so a regimen needs to be tailored for each individual. Important considerations when treating elderly patients include convenience and tolerability. This review will discuss approaches to the management of elderly patients with locally advanced and metastatic colon cancer.

X-linked inhibitor of apoptosis-associated factor l (XAFl) enhances the sensitivity of colorectal cancer cells to cisplatin

“…On the other hand, low shows the mean values of apoptosis rates from three independent experiments (***P \ 0.001). c Flow cytometry analyzes cell apoptosis after treatment with DDP which is a representative picture from at least three independent experiments dose chemotherapy would had a low treatment efficaccy and could not benefit to prolong progression free survival (PFS) or overall survival (OS) [21]. Thereafter, there is an urgent need to explore the mechanism that regulates cell sensitivity to chemotherapy drugs in a low dose.…”

Maintenance Therapy for Elderly Colorectal Cancer Patients with Bevacizumab: Single Center Experience

“…Colorectal cancer (CRC) is a commonly diagnosed cancer and ranks 3rd in incidences for those with a median age of over 70 years [15]. Treatment strategy for older CRC patients may be complicated by certain age-related impairments, philological status, the ability to tolerate treatment toxicity, and much comorbidity [16][17][18]. More clinical trial evidence is needed before decisions on treatment for older adults can be made [18].…”

KRAS biomarker testing disparities in colorectal cancer patients in New Mexico

“…Elderly patients often do not receive guideline-concordant care in CRC. The median age of CRC diagnosis in the U.S. is 69 years, making this topic especially significant [34] . Increased prevalence of medical comorbidities and organ dysfunction in the elderly are legitimate concerns regarding the initiation of cancer treatments [34] .…”